ArticleBMC microbiology2025
Emergence of Rhodotorula mucilaginosa among pet animals: a possible public health risk on the move.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Habitat-structured fungal mycobiomes at the water-gill interface of farmed red tilapia in Central Thailand: An internal transcribed spacer rRNA amplicon sequencing study.Veterinary world · 2026Article
- Rhodotorula and Phaffia: pigment producing basidiomycetous yeasts for application in aquaculture practices.Archives of microbiology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhodotorulae are environmentally ubiquitous yeasts that were originally considered non-pathogenic. However, over the last fifty years, Rhodotorula mucilaginosa (R. mucilaginosa) has established itself as an emerging opportunistic pathogen incriminated in several systemic and localized infections in humans and animals. Most of the rhodotorulosis cases were linked directly or indirectly to an immunocompromising event in the affected cases. Nevertheless, recently, a few non-immunocompromised cases were reported. In the current study, performed throughout the period from April/2023 to April/2024, 450 samples were collected from pet animals and investigated for the existence and coexistence of Rhodotorula spp. in different clinically diagnosed infectious cases. 173 (38.5%) samples showed positive direct microscopic slides of different sizes of Gram-positive budding yeast cells, 21 (4.7%). Rhodotorula isolates mixed with other yeasts and/or bacterial pathogens were recovered from nasal passages and ear canal swabs collected from dogs and cats suffering from nasal affection and otitis externa. Laboratory investigations were based on sample collection, microscopic examination, primary isolation and identification, biochemical and post-culturing characterization, antifungal susceptibility testing, VITEK 2 Compact Identification System, DNA extraction, PCR amplification, sequencing, and phylogenetic analysis. Moreover, antifungal susceptibility testing based on the standard broth microdilution test was applied to the recovered Rhodotorula isolates. In conclusion, the present findings spotlighted a prospective insight into the role of the emergence of R. mucilaginosa among pet animals and its possible public health concerns. Clinical trial number: Not Applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.